GHR Foundation

• Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change

  1 Oct 2026

• A caution in interpreting reliable cognitive decline in older adults at risk for Alzheimer's disease

  17 Sept 2026

• Remote digital cognitive assessment in a trial-ready Alzheimer's disease cohort: A scalable approach for early intervention studies

  8 Sept 2026

• Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

  1 Sept 2026

• Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants

  1 Aug 2026

• APOE and amyloid-tau pathology in cognitively unimpaired older adults

  1 Jul 2026

• Relationships between fine memory discrimination and tau burden in two independent cohorts of older adults

  9 Feb 2026

• The longitudinal association between dyslipidemia and cognitive trajectory

  23 Oct 2025

• White matter hyperintensities: relationship to amyloid and tau burden

  1 Aug 2019

Sources: api.crossref.org

• Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease

  Grants or research support, 12 Oct 2026

• Remote digital cognitive assessment in a trial-ready Alzheimer's disease cohort: A scalable approach for early intervention studies

  Grants or research support, 8 Sept 2026

• More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

  Grants or research support, 1 Sept 2026

• The Right Person, the Right Treatment, at the Right Time in Alzheimer's Disease: Insights From the 2025 Brain Aging Symposium

  Grants or research support, 1 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov